Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
FENNEC PHARMACEUTICALS INC. (FENC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/04/2023 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/09/2019 |
8-K
| Quarterly results |
| 05/09/2019 |
8-K
| Quarterly results |
| 08/16/2010 |
8-K
| Form 8-K - Current report |
| 05/13/2008 |
8-K
| Quarterly results|
Docs:
|
"Adherex Reports First Quarter 2008 Financial Results Research Triangle Park, NC, May 13, 2008—Adherex Technologies Inc. , a biopharmaceutical company devoted to solving problems for patients with cancer, announced today its financial results for the first quarter ended March 31, 2008. All amounts are in U.S. dollars. Financial Update The net loss for the three-month period ended March 31, 2008 was $4.3 million, or $0.03 loss per share, compared to a net loss of $4.0 million, or $0.05 loss per share, for the three-month period ended March 31, 2007. Operating expenses totaled $4.4 million, an increase of 8% over the same period last year. The increase in operating expenses is primarily due to $1.3 million in non-cash stock-based compensation expense for the three-month period ended March 31,..." |
|
| 11/08/2007 |
8-K
| Quarterly results|
Docs:
|
"ADHEREX REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS Research Triangle Park, NC, November 7, 2007—Adherex Technologies Inc. , a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for the third quarter ended September 30, 2007. Unless otherwise indicated, the amounts included in this press release are in U.S. dollars. Financial Update The net loss for the quarter ended September 30, 2007 was $3.2 million, or $0.02 loss per share, compared to a net loss of $4.6 million, or $0.09 loss per share, for the quarter ended September 30, 2006. Operating expenses for the quarter ended September 30, 2007 totaled $3.5 million as compared to $4.8 million in the same period in 2006. The net loss for the nine-month period ended Sep..." |
|
| 03/28/2007 |
8-K
| Quarterly results|
Docs:
|
"ADHEREX REPORTS 2006 FISCAL RESULTS Research Triangle Park, NC, March 26, 2007— Adherex Technologies Inc. , a biopharmaceutical company with a broad portfolio of oncology products under development, today reported its financial results for the twelve-month fiscal period ended December 31, 2006. All amounts are in U.S. dollars unless otherwise indicated. The net loss for the twelve-month fiscal period ended December 31, 2006 was $19.1 million, or $0.40 loss per share, compared to a net loss of $19.2 million, or $0.49 loss per share, for the twelve-month fiscal period ended December 31, 2005. Operating expenses totaled $19.1 million for the twelve-month fiscal period ended December 31, 2006 as compared to $18.3 million for the twelve-month fiscal period ended December 31, 2005. The increased..." |
|
|
|